Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term adjuvant. Found 20 abstracts

Avkshtol V, Handorf EA, Ridge JA, Leachman BK, Liu JC, Bauman J, Galloway TJ. Examining adjuvant radiation dose in head and neck squamous cell carcinoma. Head & neck. 2019 Jul;41(7):2133-42.
Ghatalia P, Koenigsberg R, Pisarcik D, Handorf EA, Geynisman DM, Zibelman M. The Evolution of Clinical Trials in Renal Cell Carcinoma: A Status Report for 2013-2016 from the ClinicalTrials.gov Website. Kidney cancer. 2017 Nov 27;1(2):151-9.   PMCID: PMC6179107
Shaikh T, Handorf EA, Murphy CT, Kutikov A, Uzzo RG, Hallman M, Horwitz EM, Smaldone MC. Contemporary Trends in the Utilization of Radiotherapy in Patients With Renal Cell Carcinoma. Urology. 2015 Dec;86(6):1165-73.
Kalbasi A, Swisher-McClure S, Mitra N, Sunderland R, Smaldone MC, Uzzo RG, Bekelman JE. Low Rates of Adjuvant Radiation in Patients With Nonmetastatic Prostate Cancer With High-Risk Pathologic Features. Cancer. 2014 Oct;120(19):3089-96.   PMCID: 4277873
Miller SJ, Alam M, Andersen JS, Berg D, Bichakjian CK, Bowen GM, Cheney RT, Glass LF, Grekin RC, Ho AL, Kessinger A, Liegeois N, Lydiatt DD, Michalski J, Morrison WH, Nehal KS, Nelson KC, Nghiem P, Olencki T, Perlis CS, Shaha AR, Tuli M, Urist MM, Wang LC, Zic JA. Dermatofibrosarcoma Protuberans. Journal of the National Comprehensive Cancer Network. 2012 Mar;10(3):312-8.   PMCID: not NIH funded
Hamstra DA, Bae K, Pilepich MV, Hanks GE, Grignon DJ, McGowan DG, Roach M, Lawton C, Lee RJ, Sandler H. OLDER AGE PREDICTS DECREASED METASTASIS AND PROSTATE CANCER-SPECIFIC DEATH FOR MEN TREATED WITH RADIATION THERAPY: META-ANALYSIS OF RADIATION THERAPY ONCOLOGY GROUP TRIALS. International Journal of Radiation Oncology Biology Physics. 2011 Dec;81(5):1293-301.   PMCID: NIHMS285956
Hayashi N, Nakamura S, Yagata H, Shimoda Y, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series. International Journal of Clinical Oncology. 2011 Oct;16(5):596-600.   PMCID: *
Sharma NK, Li TY, Chen DY, Pollack A, Horwitz EM, Buyyounouski MK. INTENSITY-MODULATED RADIOTHERAPY REDUCES GASTROINTESTINAL TOXICITY IN PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2011 Jun;80(2):437-44.   PMCID: PMC2909627
Reichardt P, Blay JY, von Mehren M. Towards global consensus in the treatment of gastrointestinal stromal tumor. Expert Review of Anticancer Therapy. 2010 Feb;10(2):221-32.   PMCID: PMC347555
Chang DT, Feigenberg SJ, Indelicato DJ, Morris CG, Lightsey J, Grobmyer SR, Copeland EM, Mendenhall NP. Long-term outcomes in breast cancer patients with ten or more positive axillary nodes treated with combined-modality therapy: The importance of radiation field selection. International Journal of Radiation Oncology Biology Physics. 2007 Mar;67(4):1043-51.
Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D, Pollack A. Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. International Journal of Radiation Oncology Biology Physics. 2005 Jun;62(2):397-405.
Konski A, Sherman E, Krahn M, Bremner K, Beck JR, Watkins-Bruner D, Pilepich M. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10). International Journal of Radiation Oncology Biology Physics. 2005 Nov;63(3):788-94.
Horwitz EM, Feigenberg SJ, Pollack A, Hanks GE, Uzzo RG. Androgen suppression plus radiation therapy for prostate cancer. JAMA-Journal of the American Medical Association. 2004 Nov 03;292(17):2084-5.
Engstrom PF, Benson A, Choti MA, Cohen AM, Doroshow JH, Fuchs C, Kiel K, Martin EW, McGinn C, Petrelli NJ, Posey JA, Skibber JM, Venook A, Yeatman TJ. NCCN Practice Guidelines for colorectal cancer. Oncology-New York. 2000 Nov;14(11A):203-12.
Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C, Donnelly J, Eisenberger MA, Escalante C, Hinds P, Jacobsen PB, Kaldor P, Knight SJ, Peterman A, Piper BF, Rugo H, Sabbatini P, Stahl C. NCCN Practice Guidelines for cancer-related fatigue. Oncology-New York. 2000 Nov;14(11A):151-61.
Russell AH, Harris J, Rosenberg PJ, Sause WT, Fisher BJ, Hoffman JP, Kraybill WG, Byhardt RW. Anal sphincter conservation for patients with adenocarcinoma of the distal rectum: Long-term results of Radiation Therapy Oncology Group Protocol 89-02. International Journal of Radiation Oncology Biology Physics. 2000 Jan 15;46(2):313-22.
Meropol NJ. Oral fluoropyrimidines in the treatment of colorectal cancer. European Journal of Cancer. 1998 Sep;34(10):1509-13.
Hoffman JP, Odwyer P, Agarwal P, Salazar H, Ahmad N. Preoperative chemoradiotherapy for localized pancreatic carcinoma - A perspective. Cancer. 1996 Aug;78(3):592-7.
Fowler WC, Hoffman JP, Eisenberg BL. Redo Hepatic Resection for Metastatic Colorectal-Carcinoma. World Journal of Surgery. 1993 Sep;17(5):658-62.
Young RC, Brady MF, Walton LA, Homesley HD, Averette HE, Long HJ. Localized Ovarian-Cancer in the Elderly - the Gynecologic Oncology Group Experience. Cancer. 1993 Jan 15;71(2):601-5.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term adjuvant

adjuvant therapy radiotherapy locally advanced-carcinoma cancer neoadjuvant prostate cancer definitive radiotherapy survival follow-up phase-iii trial chemotherapy imatinib mesylate androgen deprivation gastrointestinal suppression experience patterns of care Metastasis Prostate cancer patterns irradiation radiation deprivation fluorouracil randomized trial management phase-ii imatinib sarcoma recurrence local excision carcinoma anal sphincter HIGH-DOSE CHEMOTHERAPY Androgen Income kidney cancer adjuvant chemotherapy renal cell carcinoma mohs micrographic surgery guidelines excision her2 coloanal anastomosis residual disease progression oral chemotherapy cost-effectiveness combination breast-cancer Male Network Circulating tumor cell adverse effects ii trial CONSERVATIVE SURGERY stem-cell transplantation postoperative genitourinary morbidity immunotherapy escalation ethynyluracil rectal-cancer breast neoplasms family history advanced-carcinoma sphincter preservation hormones pancreatic neoplasms group rtog European Society of Medical Oncology treatment ovarian cancer 5-fluorouracil electrons REGIONAL NODAL 5-ethynyluracil 776c85 aneusomy NCCN Guidelines adenocarcinoma LYMPH-NODES KIT neoadjuvant hormonal-therapy competing risk failure Retrospective anti-tumor activity Age Factors epidemiology S-1 gene amplification dose-response pancreaticoduodenectomy skin radiation therapy high-dose NCCN Clinical Practice Guidelines surgery 3D-CRT deprivation therapy head and neck cancer stromelysin-3 expression 80 and over Aged radiation-therapy National Comprehensive Cancer Residence Characteristics IRRADIATION phase-ii trial tyrosine kinase pathology localized inhibitor colon-cancer quality-of-life wide capecitabine uracil postoperative radiation-therapy sunitinib non-melanoma laparotomy hormonal-therapy Polysomy Prostatectomy Hormonal ablation colorectal cancer Prostatic Neoplasms SURGICAL ADJUVANT BREAST differential-diagnosis surgical volume antineoplastic staging laparotomy 2007 arthur ga-j natl compr canc ne-v5-p557 late rectal toxicity modulation Breast neoplasm healthy-individuals methods national cancer database CONSERVING THERAPY tumors conformal radiation-therapy Radiation therapy Intensity-modulated radiotherapy statistics & numerical data prognostic-factors group protocol 92-02 dose-escalation trial nilotinib
Last updated on Thursday, April 02, 2020